Market Place
Sourcing Support
All News #Library
Biotech
Omeros Reports Primate Study Success In Oncotox-AML Program
17 Feb 2026 //
BUSINESSWIRE
Omeros Announces First Commercial Sales of Yartemlea
27 Jan 2026 //
BUSINESSWIRE
FDA approves Omeros` drug to treat transplant complication
24 Dec 2025 //
REUTERS
FDA Delays Omeros` 2nd Attempt at Transplant Drug’s Approval
18 Aug 2025 //
FIERCE BIOTECH
Omeros Submits Narsoplimab MAA to EMA for Treating TA-TMA
27 Jun 2025 //
BUSINESSWIRE
FDA Accepts BLA Resubmission for Narsoplimab for TA-TMA
07 May 2025 //
BUSINESSWIRE
Omeros Corporation to Introduce T-CAT Program at European Congress
08 Apr 2025 //
BUSINESSWIRE
Omeros Corporation to Announce Q4 and Year-end Results on March 3
26 Mar 2025 //
BUSINESSWIRE
Omeros Corporation Updates Zaltenibart Phase 3 PNH Trial Program
21 Mar 2025 //
BUSINESSWIRE
Omeros Reports Narsoplimab Results In TA-TMA Expanded Program
20 Feb 2025 //
BUSINESSWIRE
Omeros Shares Narsoplimab Data From 2025 Tandem Meetings
14 Feb 2025 //
BUSINESSWIRE
Omeros Announces Presentations on Narsoplimab for TA-TMA Treatment
10 Feb 2025 //
BUSINESSWIRE
Omeros Updates Statistical Analysis Of Narsoplimab Trial Endpoint
16 Jan 2025 //
BUSINESSWIRE
Omeros stock up after data analysis spurs BLA resubmission plan
20 Dec 2024 //
FIERCE BIOTECH
Omeros’ Narsoplimab Meets Primary Endpoint in TA-TMA Trial
19 Dec 2024 //
BUSINESSWIRE
Omeros Presents Positive Zaltenibart Data at ASH Annual Meeting
10 Dec 2024 //
BUSINESSWIRE
Omeros Provides Update on BLA Resubmission Progress
21 Nov 2024 //
BUSINESSWIRE
Omeros Announces Presentation Detailing Narsoplimab Compassionate Use
20 Feb 2024 //
BUSINESSWIRE
Omeros Provides Update on Analysis of Phase 3 Trial of Narsoplimab
16 Oct 2023 //
BUSINESSWIRE
Omeros Announces Late-Breaking Presentation of OMS906 Data at EHA
01 Jun 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.